In contrast to simian immunodeficiency viruses (SIVs), which induce immunodeficiency over a 1-to 3-year period, highly pathogenic simian-human immunodeficiency viruses (SHIVs) cause a complete, irreversible, and systemic depletion of CD4 ؉ T lymphocytes in rhesus monkeys within weeks of infection. By using small-molecule competitors specific for CCR5 and CXCR4 in ex vivo assays, we found that highly pathogenic SHIVDH12R exclusively uses CXCR4 for infection of rhesus peripheral blood mononuclear cells, whereas SIVmac239 and SIVsmE543 use CCR5 for entry into the same cells. During the period of peak virus production in SHIV DH12R-or SHIV89.6P-infected rhesus monkeys, massive elimination of CXCR4 ؉ naïve CD4 ؉ T cells occurred. In contrast, circulating CCR5 ؉ memory CD4 ؉ T cells were selectively depleted in rapidly progressing SIV-infected monkeys. At the time of their death, two SIV rapid progressors had experienced a nearly complete loss of the memory CD4 ؉ T cell subset from the blood and mesenteric lymph nodes. Thus, pathogenic SHIVs and SIVs target different subsets of CD4 ؉ T cells in vivo, with the pattern of CD4 ؉ T lymphocyte depletion being inextricably linked to chemokine receptor use. In the context of developing an effective prophylactic vaccine, which must potently control virus replication during the primary infection, regimens that suppress SHIVs might not protect monkeys against SIV or humans against HIV-1.
H
ighly pathogenic simian-human immunodeficiency viruses (SHIVs) cause a rapid, systemic, and complete loss of CD4 ϩ T lymphocytes within weeks of inoculation of rhesus monkeys, high and sustained levels (Ͼ10 7 copies per ml of plasma) of viral RNA, and death from immunodeficiency in 12-30 weeks (1) (2) (3) . This rapid and irreversible CD4 ϩ T cell-depleting phenotype is markedly different from that observed for either simian immunodeficiency virus (SIV) or HIV-1, both of which generally induce more gradual and moderate losses of CD4 ϩ T cells, and much slower development of clinical disease in macaques and humans, respectively. Surprisingly, SHIVs have proven to be more controllable by the same vaccine regimens that are ineffective against SIV (4) (5) (6) (7) . Vaccine strategies that readily and durably suppress plasma SHIV RNA levels and prevent the associated global loss of CD4 ϩ T lymphocytes only transiently control SIV viral load, and SIV-challenged macaques invariably succumb to AIDS after similar immunizations.
The distinctive features of in vivo SHIV and SIV infections enumerated above suggest that the underlying mechanism(s) of disease induction by each virus may be different. Side-by-side comparisons of CD4 ϩ T cell subsets targeted by SHIVs and SIV during infections of rhesus monkeys were therefore carried out. In the case of SIV, four (of the 10 initially inoculated) rapidly progressing animals were studied because they exhibit virological parameters and clinical symptoms that are similar to those reported for macaques infected with SHIVs (8) . Ex vivo experiments, employing competitors specific for CCR5 and CXCR4, revealed that SIVs exclusively used CCR5 to enter and spread through cultured rhesus monkey peripheral blood mononuclear cells (PBMCs), whereas SHIV DH12R used CXCR4, but not CCR5, during productive infections of the same cells. In inoculated rhesus monkeys, massive depletion of naïve CD4 ϩ T lymphocytes was observed during the period of peak SHIV production (weeks 1 to 3). In contrast, memory CD4 ϩ T cells were selectively eliminated from the blood and lymph nodes in rapidly progressing SIV-infected animals. The expression of CXCR4 on virtually all naïve and a significant fraction of memory CD4 ϩ T lymphocytes ultimately makes both subsets the target of highly pathogenic SHIVs, and explains the rapid, irreversible, and complete depletion of CD4 ϩ T cells in SHIV, but not SIV infections of macaques.
Materials and Methods
Virus and Animals. The origin and preparation of the tissue culture-derived SHIV DH12R and SHIV DH12R-CL-7 stock have been described (1, 9) . SHIV 89.6P was kindly provided by N. Letvin (Harvard University, Boston; ref. 3 ). An infectious molecular clone of SIV smE543 was generated and prepared as described (10) . Rhesus macaques (Macaca mulatta) were maintained in accordance with the guidelines of the Committee on Care and Use of Laboratory Animals (11) and were housed in a biosafety level 2 facility; biosafety level 3 practices were followed. Phlebotomies and virus inoculations [500-100,000 tissue culture 50% infectious dose (TCID 50 ) of SHIV DH12R or SHIV DH12R-CL-7 i.v., 1:500 dilution of SHIV 89.6P i.v, or 2,000 TCID 50 of SIV smE543 i.v.] were performed as described (12) .
Effect of Coreceptor-Specific Inhibitors on SIV and SHIV Replication. AMD3100 (13) was obtained from the AIDS Research and Reference Reagent Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health. AD101 (14) was provided by B. Baroudy (ScheringPlough Research Institute, Bloomfield, NJ). Chemokine coreceptor usage in PBMC was determined as described (9, 15) . APC), CCR5 (PE or APC), and isotype-matched controls (mouse IgG1, mouse IgG2, and rat IgG2). All antibodies were obtained from BD Biosciences Pharmingen (San Diego) and analyzed by four-color flow cytometry (FACSCalibur; BD Biosciences Immunocytometry Systems). For CD4 ϩ T lymphocyte subset frequencies, a CD4 ϩ small-lymphocyte gate was used for further phenotypying (16, 17) . Data analysis was performed by using CELLQUEST PRO (BD Biosciences) and F LOWJO (TreeStar, San Carlos, CA). The statistical analysis was performed by using STATVIEW software (Abacus Concepts, Berkeley, CA). The significance of differences between paired groups was analyzed with the Mann-Whitney U test.
Results

SIV and SHIVs Use Different Coreceptors to Establish Infections of
Cultured Rhesus Monkey PBMC. Small-molecule coreceptortargeted inhibitors, specific for CCR5 or CXCR4, were used to assess coreceptor utilization by SIVs and SHIVs for macaque PBMCs. As shown in Fig. 1 , SIV smE543 , SIV mac239 , and SIV mac316 spreading infections were readily suppressed by the CCR5-specific AD101 (14) , but not by the CXCR4 inhibitor, AMD3100 (13) . The opposite result was observed with a molecularly cloned derivative of the highly pathogenic SHIV DH12R , designated SHIV DH12R-CL-7 (18) : infection of monkey PBMC was completely blocked by the CXCR4-targeting AMD 3100, but not by the CCR5 inhibitor AD101. These results indicate that the three SIV strains used CCR5 and the highly pathogenic SHIV DH12R-CL-7 used CXCR4 to enter and spread in cultured rhesus macaque PBMC. Similar findings have been reported for uncloned SHIV DH12R and SHIV 89.6PD (9, 15) . Coreceptor use by SIVs (A-C) and SHIVDH12R-CL-7 (D). SIVsmE543-3, SIV mac239, SIVmac316, and SHIVDH12R-CL-7 were spinoculated onto rhesus PBMCs in the presence of the indicated amounts of chemokine receptor inhibitors. The reverse transcriptase activity released into the medium on day 5 after infection was determined in the absence (dashed line) or presence of inhibitor. In addition to the CD4 molecule, primate lentiviruses also use chemokine receptors (primarily CCR5 and CXCR4) to enter their target cells. As shown in Fig. 2c for both a representative monkey and a total of 30 uninfected animals, Ͼ80% of circulating CD4 ϩ T lymphocytes were CXCR4-positive (mean ϭ 83%), and Ͻ10% (mean ϭ 8.6%) expressed CCR5. Chemokine receptor expression was also measured on naïve and memory subsets of monkey CD4 ϩ T cells. After initially gating on CD95 low CD28 high -naïve lymphocytes, individual samples were stained for CXCR4 or CCR5. Virtually all of the naïve cells were positive for CXCR4 and negative for CCR5 in the representative animal shown (Fig. 2d) . When extended to a total of 11 uninfected macaques, the majority (mean ϭ 95.7%) of naïve CD4 Fig. 3a . All three animals generated peak levels of plasma viremia between days 10 and 21 after inoculation and sustained high virus loads thereafter. As expected, the two monkeys (RH447 and RH508) inoculated with the pathogenic SHIVs both experienced a rapid, precipitous, and complete loss of CD4 ϩ T cells, whereas the SIV-infected macaque (RHCK2K) had fluctuating but relatively normal levels of CD4 ϩ T lymphocytes during the acute phase of infection.
To ascertain whether distinct CD4 ϩ T cell subsets were targeted by pathogenic SHIVs and SIVs, flow cytometric analyses were performed on PBMC samples collected during the first 10 weeks after virus inoculation, by using the two combinations of mAbs that distinguish memory and naïve lymphocytes. As shown in Fig. 3b , SHIV DH12R and SHIV 89.6P both induced the rapid depletion of naïve CD4 Two of the rapidly progressing SIV smE543 -infected macaques (RHCK2K and RHCK2F) were killed on weeks 15 and 31 after inoculation, respectively, because of their deteriorating clinical condition. FACS analyses of CD4 ϩ T cells from the blood and mesenteric lymph node suspensions, employing the two combinations (CD95͞CD28 or CD45RA͞CD11a) of mAbs, revealed that Ͼ95% of the samples consisted of naïve cells (Fig. 4) not shown), further validating their naïve cell status. Thus, at the time of death, both of the rapidly progressing SIV smE543 -infected monkeys had experienced a nearly complete loss of memory CD4 ϩ T cells from the blood and lymphoid tissues. A similar analysis could not be performed on specimens collected at the necropsy of immunodeficient SHIV-infected animals because of the extremely low levels of CD4 ϩ T lymphocytes in the blood (Ͻ5 cells per microliter) and lymphoid tissues (19) .
FACS analyses were also conducted on CXCR4-and CCR5-expressing CD4 (Fig. 3c) .
The flow cytometric analyses of CD4 ϩ T lymphocytes from 10 SHIV (8 SHIV DH12R and 2 SHIV 89.6P ) and 4 rapidly progressing SIV smE543 -infected monkeys at weeks 0 and 6 are summarized in Fig. 5 . The data show that the highly pathogenic SHIVs preferentially target the depletion of CXCR4 
Discussion
We have shown that highly pathogenic SHIVs and SIVs target different subsets of CD4 ϩ T cells in vivo, explaining the distinctive laboratory findings and clinical courses induced by each virus in infected rhesus monkeys. Ex vivo, SHIVs exclusively used CXCR4 to enter and spread through cultured macaque PBMCs. In infected monkeys, SHIVs cause a nearly complete depletion of naïve CD4 ϩ T lymphocytes within 4 weeks of inoculation and the elimination of virtually all of the central memory cells by week 10. In contrast, SIV mac239 and SIV smE543 both used CCR5, but not CXCR4, to infect cultured rhesus monkey PBMCs. CCR5 is exclusively expressed on memory CD4 ϩ T lymphocytes and at significantly higher levels on cells that reside in nonlymphoid tissues (e.g., in the gastrointestinal tract and lung; refs. 20 and 21). As a consequence, the SIV-infected monkeys exhibiting rapid disease progression in this study experienced the selective loss of circulating CCR5 ϩ CD4 ϩ memory T cells during the first 6 weeks of infection. In two SIV-infected animals killed at weeks 15 and 31 with severe clinical disease, Ͼ95% of the CD4 ϩ T lymphocytes in the blood and lymph nodes were naïve T cells. Thus, the pattern of CD4 ϩ T lymphocyte depletion induced by SHIVs and SIVs is inextricably linked to the chemokine coreceptor used by each virus. One could therefore argue that in the context of an effective prophylactic vaccine, which must potently control virus replication during the initial weeks of the primary infection, regimens that suppress SHIVs might not be effective against SIV in monkeys and HIV-1 in humans. If X4 SHIVs are to be used to evaluate antibody-based vaccine strategies, it would be more appropriate to use sterilizing protection, rather than preventing the complete loss of CD4 ϩ T lymphocytes, as the endpoint for vaccine efficacy.
The specific targeting and rapid elimination of CXCR4-positive CD4 ϩ T cells in the blood in macaques inoculated with pathogenic SHIVs is consistent with reports describing the enhanced cytopathicity and more vigorous replicative properties of syncytium-inducing (primarily X4) HIV-1 variants compared with nonsyncytium inducing (exclusively R5) strains in vitro (22, 23) . Similar results have been obtained by using the ex vivo human tonsil histoculture system in which X4 HIV-1 variants were found to be more cytopathic than R5 viruses (24) (25) (26) . Although comparable results have also been reported for X4 HIV-1 isolates tested in the SCID-hu-Thy-Liv mouse model (27) , the presence of large pools of immature T lymphocytes͞ thymocytes in that system makes it less applicable to primate lentivirus infections, in monkeys and humans, that target CD4 ϩ T cells that have survived thymic selection.
It has been recognized for Ͼ10 years that the emergence of X4 variants in HIV-1-infected individuals is associated with accelerated CD4 ϩ T cell depletion and more rapid progression to AIDS Fig. 4 . At the time of death, two SIV-infected monkeys had lost virtually all of their CD4 ϩ memory T cells from the blood and lymph nodes. EDTA-treated blood samples or mesenteric lymph node suspensions, collected before death from macaques RHCK2K and RHCK2F, were gated on CD4 ϩ T cells and stained for the indicated surface markers that distinguish naïve and memory cells. The percentages are indicated for each CD4 ϩ T cell subset. Fig. 5 . Changes in the levels of naïve (a), memory (a), CXCR4 ϩ (b), and CCR5 ϩ (b) CD4 ϩ T cells in rhesus monkeys inoculated with SHIVs and SIVs at week 0 and week 6 after infection. The significance of differences between each paired group was analyzed by using the Mann-Whitney U test. (22, 28) . The CXCR4 coreceptor, used by late-appearing X4 viruses, is primarily expressed on cells with a resting naïve phenotype. CXCR4 ϩ cells also comprise the major population of CD4 ϩ T lymphocytes in the circulation and lymphoid tissues (Fig. 2c and  ref. 24) . The CCR5 chemokine coreceptor, on the other hand, is expressed on a much smaller pool of activated memory CD4 ϩ T cells; some memory T lymphocytes express both CCR5 and CXCR4 (Fig. 2d and ref. 24) . Thus, a report showing that carriers of X4 HIV-1 variants have 30-to 70-fold higher frequencies of virus-infected naïve cells than individuals who harbor only R5 virus (29) is consistent with the coreceptor utilization properties of each viral strain. The accelerated and specific decline of naïve CD4 ϩ T lymphocytes after the emergence of X4 variants is a further reflection of coreceptor-mediated targeting and depletion of this abundant T cell subset (30) .
Multiple studies have shown that resting and͞or naïve PBMC in culture are highly refractory to HIV-1 infection, whereas activated memory cells are quite susceptible (31) (32) (33) (34) (35) . The block to HIV-1 replication in resting PBMCs is not presently understood, although the small pool sizes of ribonucleotides, deoxyribonucleotide triphosphates, and ATP in quiescent cells may play a role (36) . Nonetheless, HIV-1 has been recovered from CD45RA ϩ ͞CD62L ϩ naïve CD4 ϩ T lymphocytes of infected individuals (37) , and this same T cell subset becomes preferentially infected and depleted in human tonsil explant cultures by X4 virus strains (38) . It has also been recently reported that although resting CD45RO ϩ CD57 Ϫ CD4 ϩ memory cells are the predominant virus-producing cell in HIV-1-infected persons, naïve CD4 ϩ T lymphocytes are also virus positive at a 10-fold lower frequency in the same individuals (39) . At present, we have no definitive information as to whether naïve CD4 ϩ T cells in SHIV-infected rhesus monkeys are the sole source of the prodigious viremia observed at week 2 after inoculation (Fig.  3) . Nevertheless, in preliminary experiments, we were unable to demonstrate any increase in activation͞proliferation markers such as CD25, CD69, or Ki-67 on CD4 ϩ T cells in the blood or lymph nodes, before or during the peak viremia associated with the SHIV infection (Y.N., unpublished work), suggesting that they are the source of prodigious amounts of progeny virions generated.
The induction of immunodeficiency by pathogenic SHIVs requires the elimination of virtually all CD4 ϩ T lymphocytes. Although CXCR4 is expressed on both naïve and memory CD4 ϩ T lymphocyte subsets, its higher surface expression on the former (Fig. 2d) may explain why the loss of memory cells lags behind that of naïve lymphocytes when SHIV-induced depletions are complete (Fig. 3b) . This depletion of naïve CD4 ϩ T lymphocytes may also markedly impact the pool of virus-specific memory CD4 ϩ T cells, resulting in an ineffective antiviral immune response. In contrast, after the inoculation of nonpathogenic SHIVs or when the SHIV-induced loss of CD4 ϩ T cells is only partial or transient (12) , the resulting infections are rarely associated with clinical symptoms; such SHIV-infected animals usually remain disease-free for several years (18) . In monkeys experiencing partial depletions of CD4 ϩ T cells, the loss primarily affects the naïve cell subset (Y.N., unpublished work). The preservation of CD4 ϩ memory T lymphocytes in these SHIV-infected macaques is very likely responsible for their long-term asymptomatic clinical course. Similarly, the relative sparing of CD4 ϩ memory T cells during SHIV versus SIV infections may explain why comparable vaccine regimens appear to be more effective against SHIV challenges.
Compared with SHIVs, SIV infections of Asian macaques usually proceed at a much slower pace with the development of clinical disease, occurring 1-2 years after virus inoculation (40, 41) . During acute SIV infections, marked depletions of CD4 ϩ T cells from the gut-associated lymphoid tissues, not blood and lymph nodes, have been reported (42, 43) . This loss specifically affects activated memory cells. In the 25-30% of SIV-infected rhesus monkeys, termed rapid progressors, which develop persistent antigenemia, high levels of plasma viremia, no SIVspecific humoral responses, and immunodeficiency within 3-4 months after inoculation, only minor declines in circulating CD4 ϩ T lymphocytes have been reported in animals experiencing severe immunologic deficits (8) . This result was also observed in the cohort of the four SIV-infected macaques in the present study. In these rapid progressors, SIV initially targeted CD4 ϩ central memory cells, which express high levels of CCR5, and subsequently infected CD4 ϩ effector memory lymphocytes, which express lower levels of the chemokine receptor (Fig. 2d) . This targeting resulted in marked depletions of both memory subsets in the blood during the initial weeks of the acute infection (Figs. 3b and 5 ). In contrast, conventional SIV progressors only experience the partial loss of circulating CD4 Taken together, the SIV͞macaque system would appear to be a better model for HIV-1-induced immunodeficiency than would the SHIV system. First, R5, but not X4-using HIV-1 isolates, are commonly recovered during the asymptomatic phase of infection (44, 45) . Like SIV, such R5 HIV-1 strains preferentially infect CD4 ϩ memory T lymphocytes and induce clinical disease over extended periods of time without requiring the total elimination of CD4 ϩ T cells. These facts notwithstanding, there are features of HIV-1 infections never observed with SIV, such as the emergence of X4 variants in late-stage individuals with severe disease. Whether the latter HIVs spontaneously arise de novo from R5 predecessors or are archival remnants of X4 strains that were readily controlled͞out-competed after the primary infection, these viruses share multiple properties with the highly pathogenic SHIVs in macaques, and their appearance heralds a rapidly deteriorating clinical course in individuals with an underlying dysfunctional immune system.
